Pub. Date : 2004 Oct 15
PMID : 15217830
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Furthermore, PK + bortezomib activates c-Jun NH2 terminal kinase (JNK), which translocates to mitochondria, thereby facilitating release of cyto-c and Smac from mitochondria to cytosol. | Bortezomib | mitogen-activated protein kinase 8 | Homo sapiens |
| 2 | Furthermore, PK + bortezomib activates c-Jun NH2 terminal kinase (JNK), which translocates to mitochondria, thereby facilitating release of cyto-c and Smac from mitochondria to cytosol. | Bortezomib | mitogen-activated protein kinase 8 | Homo sapiens |
| 3 | Blocking JNK, by either dominant-negative mutant (DN-JNK) or cotreatment with a specific JNK inhibitor SP600125, abrogates both PK + bortezomib-induced release of cyto-c/Smac and induction of apoptosis. | Bortezomib | mitogen-activated protein kinase 8 | Homo sapiens |
| 4 | Blocking JNK, by either dominant-negative mutant (DN-JNK) or cotreatment with a specific JNK inhibitor SP600125, abrogates both PK + bortezomib-induced release of cyto-c/Smac and induction of apoptosis. | Bortezomib | mitogen-activated protein kinase 8 | Homo sapiens |
| 5 | Blocking JNK, by either dominant-negative mutant (DN-JNK) or cotreatment with a specific JNK inhibitor SP600125, abrogates both PK + bortezomib-induced release of cyto-c/Smac and induction of apoptosis. | Bortezomib | mitogen-activated protein kinase 8 | Homo sapiens |